Go to the list of all blogs
Anchiano to issue shares on Nasdaq
Anchiano to issue shares on Nasdaq
Anchiano Therapeutics Ltd. is expected to issue 2.4 million shares at $14.55 each Tuesday on the Nasdaq. The company is developing a single biologic candidate to treat bladder and other cancers.
Anchiano has had promising trial results, strong existing investor support of the IPO, and a low IPO valuation, but the early stage of its development may mean the IPO is more appropriate for high risk, long-term life science investors.
Related Ticker: GNRX
Industry description
The index includes exchange-listed companies, on a global basis, that derive a significant proportion of their revenues (or that have the potential to derive a significant proportion of their revenues) from the generic drug industry, or that have a primary business focus on the generic drug industry. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. It is non-diversified.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information
General Information
Category Health
Profile
Details
Category
Health
Address
335 Madison Ave.
19th Floor
New York, NY 10017
Phone
888-658-8287
Web
www.marketvectorsetfs.com
Interact to see
Advertisement
Advertisement